Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

$RXRX ($RXRX) Releases Q1 2026 Earnings

None

$RXRX ($RXRX) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of -$0.22 per share, beating estimates of -$0.28 by $0.06. The company also reported revenue of $6,470,000, missing estimates of $16,093,050 by $-9,623,050.

You can see Quiver Quantitative's $RXRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

$RXRX Insider Trading Activity

RXRX Insider Trades

$RXRX insiders have traded $RXRX stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:

  • BLAKE BORGESON has made 0 purchases and 5 sales selling 860,000 shares for an estimated $3,525,800.
  • CHRISTOPHER GIBSON has made 0 purchases and 10 sales selling 400,000 shares for an estimated $1,582,000.
  • NAJAT KHAN (CEO and President) has made 0 purchases and 2 sales selling 152,701 shares for an estimated $643,251.
  • BEN R TAYLOR (Chief Financial Officer) has made 0 purchases and 3 sales selling 42,765 shares for an estimated $157,703.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$RXRX Hedge Fund Activity

We have seen 201 institutional investors add shares of $RXRX stock to their portfolio, and 130 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$RXRX Analyst Ratings

Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • JP Morgan issued a "Overweight" rating on 12/17/2025

To track analyst ratings and price targets for $RXRX, check out Quiver Quantitative's $RXRX forecast page.

$RXRX Price Targets

Multiple analysts have issued price targets for $RXRX recently. We have seen 4 analysts offer price targets for $RXRX in the last 6 months, with a median target of $9.0.

Here are some recent targets:

  • Priyanka Grover from JP Morgan set a target price of $10.0 on 04/30/2026
  • Michael Ryskin from B of A Securities set a target price of $6.0 on 02/26/2026
  • Gil Blum from Needham set a target price of $8.0 on 02/26/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles